Vital Prospects Clinical Research Institute, PC | Tulsa, OK

Research site

(Unclaimed)

Location

7307 S Yale Avenue, Suite 200, Tulsa, Oklahoma, United States of America

Site insights

Top conditions

Top treatments

Upadacitinib

PF-06700841

PF-06651600

OM-85

Orticumab

CDX-0159

Ritlecitinib

Lebrikizumab

PF-07038124

DUPIXENT®

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

9 of 27 total trials

A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases

The main aim of this study is to evaluate the PK, safety, tolerability and immunogenicity of subcutaneous (SC) administration of TAK-881 in adult and...

Enrolling

Primary Immunodeficiency Diseases (PID)

Biological: HYQVIA

Biological: TAK-881

A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata (BRAVE-AA-PEDS)

The main purpose of this study is to determine the efficacy and safety of baricitinib for the treatment of severe or very severe alopecia areata (hai...

Enrolling

Hair Diseases

Alopecia

Drug: Placebo

Drug: Baricitinib

A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms (OptIMMize-1)

Psoriasis is a chronic, systemic, inflammatory disease in which skin cells build up and develop thick, red and white scaly patches on the skin. There...

Active, not recruiting

Psoriasis

Drug: Ustekinumab

Drug: Risankizumab

A Study to Assess the Efficacy and Safety of Daily OM-85 in Young Children With Recurrent Wheezing

This study will assess the efficacy and safety of daily OM-85 treatment compared to placebo in children aged 6 months to 5 years with recurrent wheez...

Enrolling

Wheezing Lower Respiratory Illness

Recurrent Wheezing

Drug: Placebo

Drug: OM-85

A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (Level Up)

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not...

Active, not recruiting

Atopic Dermatitis

Drug: Upadacitinib

Drug: Dupilumab

A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2)

The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate...

Active, not recruiting

Atopic Dermatitis

Drug: Upadacitinib

Drug: Placebo for Upadacitinib

A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (AD Up)

The objective of this study is to assess the efficacy and safety of upadacitinib combined with topical corticosteroids (TCS) for the treatment of ado...

Invitation-only

Atopic Dermatitis

Drug: Placebo

Drug: Upadacitinib

Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)

This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.

Active, not recruiting

Atopic Dermatitis

Biological: Lebrikizumab

Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria (CALM-CSU)

Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects with Chronic Spontaneous Urtica...

Enrolling

Chronic Spontaneous Urticaria

Drug: Placebo

Drug: Oral EP262